| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,1
* Department of Physiology, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112; and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana 46202
1 To whom requests for reprints should be addressed at Department of Cellular and Integrative Physiology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202. E-mail: jtune{at}iupui.edu
 |
Abstract |
|---|
 Top Abstract IntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
Key Words: coronary blood flow • adipokine • leptin • resistin • adiponectin • tumor necrosis factor-
|
Introduction |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
For more than a century the burden of obesity has been documented in medical literature and textbooks. By the 1920s obesity was recognized as a major source of morbidity and mortality in Western society. In the 1928 edition of Cecil’s Textbook of Internal Medicine, obesity was clinically defined as "a state in which the amount of fat stored in the body is excessive." Also, the text referenced data from life insurance companies conclusively demonstrating an association between obesity and shortened life expectancy; however, the mechanisms by which obesity led to early mortality remained elusive at the time. Curiously, no mention of an association between obesity and cardiovascular disease was noted with the exception of a modest elevation in arterial pressure that tended to decrease with weight loss. It was, however, clear at the time that obesity conferred a predisposition for type 2 diabetes upon those afflicted (3).
By 1950 obesity was known to markedly burden the cardiovascular system, but most clinical studies to date had only examined the anatomic, nutritional, metabolic, and endocrine aspects of the disease (4). Around the same time heart disease became the number one killer in the United States. As a result, approximately 50 years ago the United States Public Health Service started a large-scale study to investigate cardiovascular disease. Framingham, Massachusetts, was selected as a study site from which a large cohort of men and women was selected and followed (5). The study soon led to the identification of a number of modifiable risk factors for heart disease including obesity. The impact of obesity, especially when the associated glucose intolerance and hypertension were considered, on the incidence of coronary artery disease was staggering (5). Medicine was forever changed and a revolution in discovery resulted, as obesity and adipose biology have become major themes in contemporary clinical and scientific investigation. Thus, a clear association between obesity and coronary artery disease has materialized and fueled the discovery and study of several fat-derived hormones (adipokines) and their effects on cardiovascular tissues.
A major advancement in our understanding of adipose biology came with the cloning of the mouse obesity gene (ob) and its human homolog in 1994 (6). The product of the ob gene, leptin, was initially implicated in regulation of energy balance and metabolism (7). However, in recent years much attention has been given to elucidating the effects of leptin on the cardiovascular system. Since the discovery of leptin, other adipokines, including resistin and adiponectin, have emerged as potential players in the pathogenesis of cardiovascular disease in the overweight and obese. Additionally, the acute-phase reactants tumor necrosis factor (TNF-) and plasminogen activator inhibitor-1 (PAI-1) have evolving roles in the pathogenesis of vascular disease; however, the focus of this survey will be on the roles of leptin, adiponectin, and resistin in coronary vasomotor function.
It is the intent of this review to specifically summarize the coronary vascular effects of the aforementioned molecules based on the current literature.
|
Leptin |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
Based on these studies, most consider leptin to be an antiobesity hormone due to its experimental effects on metabolism and food intake; however, according to a recent review by Ren (20), others argue that leptin has been inappropriately labeled as a hormone that minimizes weight gain in those exposed to an environment of readily available calories. Plasma leptin concentration is directly proportional to mean food intake over a period of days to weeks. Thus, it is hypothesized that a decrease in plasma leptin concentration serves as a short-term adaptation to starvation or famine (21). Reduced plasma leptin concentration results in decreased central sympathetic nervous outflow and mobilization of energy stores via stimulation of glucocorticoid secretion (22).
Since its discovery, leptin has gained much attention not only in endocrine and metabolism research but in cardiovascular science as well. Plasma leptin concentrations reported in normal, healthy humans are ~3–5 ng/ml, with concentrations in morbidly obese humans ranging as high as 90–95 ng/ml (18). Hyperleptinemia (elevated plasma leptin concentration), which is practically universal in obese humans (7), is an independent risk factor for cardiovascular disease (20). More specifically, elevated plasma leptin is a predictor of first myocardial infarction (23) and an independent risk factor for ischemic and hemorrhagic stroke (24). Accordingly, leptin has been deemed a component of the metabolic syndrome of obesity, insulin resistance, hypertension, and dyslipidemia; and high circulating plasma leptin levels are thought to play a role in the hastened development of coronary artery disease in obesity (25). Thus, there has been a strong impetus to study leptin among clinical and basic cardiovascular scientists.
Hyperleptinemia has been implicated in various biologic processes that are integral components of the pathogenesis of coronary artery disease. These processes include cytokine signaling (20) and the up-regulation of phagocytosis and production of proinflammatory cytokines such as TNF- (26) and C-reactive protein (27), which exert proinflammatory effects on endothelial cells (28). Also, leptin has been shown to promote platelet aggregation and thrombosis in human obesity (29–31). A recent review by Beltowski (32) in Atherosclerosis nicely outlines the role of leptin in the pathogenesis of atherosclerosis. However, it must be noted that in spite of the mass of studies demonstrating that leptin may exert proatherogenic effects both in vivo and in vitro and several clinical studies suggesting that high plasma leptin concentration is associated with atherosclerosis, no direct evidence to date demonstrates a precise role for leptin in the pathogenesis of atherosclerotic disease (32).
In addition to studies dealing with atherosclerosis, the vasomotor effects of leptin have become the focus of ongoing research. Since its discovery, leptin has been shown to exert a variety of effects in many tissues, including vasomotor effects at various peripheral targets (33, 34). In the late 1990s leptin gained attention as an activator of the sympathetic nervous system. It was shown that leptin not only stimulates central sympathetic nervous outflow (as cited above) but is also involved in regional sympathetic nerve activation (14). More specifically, many studies have demonstrated that leptin increases renal sympathetic nervous activity and raises peripheral vascular resistance and mean arterial pressure (11, 14, 17–19). Excellent reviews by Hall et al. and Haynes et al. (13, 15) in recent years nicely summarize the role of leptin in sympathetic nervous dysfunction, hypertension, and renal disease.
In 2000 a study by Kimura et al. (35) suggested that leptin is involved in nitric oxide–mediated endothelium-dependent vasodilation. Thus, a paradox arose in that leptin, which at the time had already been relatively extensively studied as a mediator of sympathetic-mediated increases in vascular resistance, was shown to be a mediator of vasodilation. Subsequent studies seemed to validate the hypothesis that leptin induces nitric oxide–dependent vasodilation (35–37). In vitro studies supported these findings, demonstrating that leptin induces nitric oxide release from human aortic endothelial cells via phosphorylation of Akt kinase at Ser 473 and Thr 308 and activation of endothelial nitric oxide synthase (eNOS) via phosphorylation at Ser 1177 (38, 39). Incongruently, others were finding leptin-mediated vasodilation to be nitric oxide independent (36, 40), with some convinced that both are partially true. The confusion was likely attributable in part to differences in species and technical experimental design. Also, the majority of these studies were conducted using very high (pharmacologic) concentrations of leptin that are well outside the reported physiologic and pathophysiologic plasma ranges; thus, the findings must be interpreted with caution. These studies were all conducted in noncoronary vascular beds.
A study in 2003 by Matsuda et al. (41) demonstrated that leptin-mediated coronary vasodilation in humans is nitric oxide independent. This finding was somewhat inconsistent in that epidemiologic studies had linked leptin to increased risk for myocardial infarction (23); however, it was the first study to analyze the direct effects of leptin on coronary vasomotor function. The subjects were all undergoing cardiac catheterization for angina, and some were diabetic and/or smokers; therefore, the findings should be interpreted cautiously when considering the physiologic effects of leptin on coronary vasomotor function in the healthy heart. Unfortunately, Matsuda et al. did not report myocardial oxygen consumption (or a clinically acceptable index thereof [e.g., pressure-rate product]) in their study. Thus, it is impossible to determine whether the demonstrated coronary vasodilatory effect of leptin was due to direct action at endothelial or vascular smooth muscle or simply the result of increased myocardial metabolic rate (e.g., via activation of the regional sympathetic nervous system). Furthermore, at the time of the Matsuda study the expression of leptin receptors in coronary arteries had not been studied.
A study by Knudson et al. (42) in 2005 aimed to further characterize the effects of leptin on coronary vasomotor function and attempted to resolve some of the disparities present in the literature. Using reverse transcriptase–polymerase chain reaction (RT-PCR) and immunocytochemistry analyses, Knudson et al. demonstrated that the long-form leptin receptor gene (ObRb) is expressed and signaling-competent long-form receptors are present in confluent cultures of human coronary artery endothelial cells. Additionally, RT-PCR analysis confirmed the expression of the ObRb gene in canine left circumflex coronary arteries (42). Leptin receptor gene expression had been previously demonstrated in human umbilical vein endothelial cells (43); however, the Knudson study was the first investigation to demonstrate expression of the leptin receptor gene and the presence of the signaling-competent leptin receptor protein in coronary arteries.
Additionally, Knudson et al. (42) demonstrated that high pharmacologic concentrations of leptin induce nitric oxide–dependent (inhibited by NG-nitro-L-arginine methyl ester [L-NAME] as well as endothelial denudation) vasodilation of pressurized coronary arterioles isolated from Wistar rats, lean Zucker rats, and normal mongrel dogs. This finding was consistent with other studies that had demonstrated that leptin induces vasodilation through eNOS; however, leptin-mediated coronary vasodilation was only observed at extremely high leptin concentrations. The normal range for plasma leptin in healthy humans is 3–5 ng/ml, and concentrations reported in obese humans are in the range of 8–90 ng/ml (18, 44, 45). Significant coronary arteriolar vasodilation was not observed until leptin concentrations reached approximately 160 ng/ml (10 nmol/L). Therefore, it is apparent that leptin-induced nitric oxide–dependent coronary vasodilation is a pharmacologic phenomenon that probably does not occur at physiologically or pathophysiologically relevant leptin concentrations. This hypothesis was tested by Knudson et al. (42) using open-chest dogs. Direct intracoronary infusion of leptin at physiologic and pathophysiologic concentration ranges had no effect on coronary blood flow, myocardial oxygen consumption, mean aortic blood pressure, or heart rate. To negate the possibility that leptin-mediated regional sympathetic activation (i.e., stimulation of alpha receptors on medium sized coronary arteries) masks nitric oxide–mediated coronary vasodilation, open-chest coronary blood flow experiments were also conducted in the presence of the ganglionic blocker, hexamethonium. As expected, since leptin alone had no hemodynamic effects, no changes from baseline in coronary blood flow, myocardial oxygen consumption, or systemic hemodynamics were observed when leptin was administered in the presence of sympathetic ganglionic blockade. Conclusively, despite the body of literature implicating leptin as an endothelium-dependent vasodilator, relevant concentrations of leptin probably have little direct effect on coronary blood flow or cardiac dynamics.
Of interest, Knudson et al. (42) also demonstrated that concentrations of leptin in the obese range impair acetylcholine-mediated coronary vasodilation in open-chest dogs and acetylcholine-mediated relaxation of isolated circumflex coronary artery rings (i.e., leptin induces significant coronary endothelial dysfunction acutely both in vitro [Fig. 1A
] and in vivo [Fig. 1B]). Interestingly, lower (physiologic) concentrations of leptin had no effect on acetylcholine-mediated coronary artery relaxation either in vitro (Fig. 1A) or in vivo (Fig. 1B). In this study, leptin concentrations in the obese range did not affect endothelium-independent coronary vasodilation to sodium nitroprusside (Fig. 1C). Thus, the effect of leptin on coronary vasomotor responses was specific for endothelial-mediated dilation/relaxation. A study by Sundell et al. (46) examined coronary flow reserve in obese and nonobese subjects using positron emission tomography and demonstrated that serum leptin concentration is inversely related to adenosine-stimulated myocardial blood flow. These results suggest that leptin may have a role in reduced myocardial blood supply in obesity. These findings correlate with the plethora of epidemiologic studies linking leptin to risk for cardiovascular disease. The findings by Knudson et al. and Sundell et al. serve to strengthen the hypothesis that leptin is a key player in the pathogenesis of coronary atherosclerotic disease by way of mediating coronary endothelial dysfunction, which according to the Ross hypothesis (47) precedes overt atherosclerotic disease. Currently the precise mechanism(s) of leptin-mediated coronary endothelial dysfunction remains unknown.
|
In summary, in the coronary circulation, leptin at physiologically relevant concentrations is not directly vasoactive; nonetheless, the long-form leptin receptor is present on human coronary endothelial cells and is expressed in dog coronary arteries. Further, concentrations of leptin in the obese range appear to have deleterious effects on coronary endothelial function and myocardial blood flow acutely; however, the mechanistic contribution of chronic hyperleptinemia to the initiation and development of coronary artery disease must be further explored.
|
Adiponectin |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
Further characterization of the biologic role of adiponectin resulted in the demonstration of adiponectin release from adipocytes increasing in response to activation of peroxisome proliferator activator receptors (e.g., PPAR-
) (53). The importance of adiponectin was most realized when it was demonstrated to be an insulin-sensitizing molecule (54–56). Further, it was demonstrated that the mechanism by which the insulin-sensitizing agents thiazolidinediones (TZDs, also known as "-glitazones") induce positive metabolic effects in type 2 diabetics is linked to an increase in adiponectin levels (57). Although the precise mechanism by which TZDs increase adiponectin levels remains unclear, much is now known regarding the cellular effects of these agents (58). An excellent review by Ferre (59) outlines the proposed mechanisms of adiponectin release, with attention given to metabolic syndrome and PPAR- stimulation by TZDs. Another interesting review by Klein et al. (60) encompasses novel therapeutic strategies relating to adipose tissue targets.
The marked differences in plasma adiponectin concentrations between healthy and obese subjects stimulated interest in the molecule and the development of hypotheses regarding the role of adiponectin in the long observed, hastened development of vascular disease in obesity, metabolic syndrome, and type 2 diabetes. As with leptin, epidemiologic studies stratifying the risk of vascular pathology attributable to adiponectin ensued. Low plasma adiponectin concentrations (hypoadiponectinemia) are an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain (61). Also, decreased circulating adiponectin levels in obesity are associated with an increased risk of coronary artery disease (62–65) and myocardial infarction (66). Additionally, adiponectin is linked to future coronary events in men with type 2 diabetes (67). Hypoadiponectinemia is also associated with platelet activation in carotid atherosclerosis (68). Interestingly, unlike leptin, adiponectin may not be associated with an increased risk of cerebrovascular accident (69).
Given the multitude of studies linking adiponectin to cardiovascular disease, adiponectin replacement therapy holds promise in the treatment of metabolic syndrome and obesity. Many studies have examined the effects of raising adiponectin levels in those at risk for cardiovascular disease and events, most of which have employed TZD therapy as a means of increasing circulating adiponectin levels. Such studies have demonstrated that pioglitazone increases adiponectin and subsequently reduces TNF- levels in type 2 diabetic patients (70); adiponectin delivered via an adenovirus vector reduces blood pressure in adiponectin-deficient, obese, KKA, and adiponectin knock-out mice (71); rosiglitazone therapy increases adiponectin levels and high-density lipoprotein cholesterol levels while reducing C-reactive protein, interleukin 6 (IL-6), IL-18, and plasma triglycerides in humans with metabolic syndrome (72, 73). A recent review by Han et al. (74) does an excellent job of describing the beneficial vascular and metabolic effects of PPAR activators. When reviewing these results, one cannot ignore the prospective therapeutic benefits of increasing plasma adiponectin in obese patients with metabolic syndrome and vascular disease. However, the mechanisms by which adiponectin provides improvement in, or in some cases reversal of, many features of metabolic syndrome have not been clearly defined. Some evidence points toward the anti-inflammatory effects of adiponectin (see below).
The precise role of adiponectin in the pathogenesis of vascular disease is likely complex and much remains to be delineated. Chronic inflammation is a recurring theme in metabolic-mediated vascular disease. As discussed previously, leptin exerts many pro-inflammatory effects; conversely, adiponectin is associated with induction of anti-inflammatory cytokine production (IL-10 and IL-1RA among others) (75). A study by Johns et al. in 2005 demonstrated that rosiglitazone therapy reduces E-selectin, P-selectin, and intercellular adhesion molecule 1 expression as well as leukocyte rolling in obese Zucker cremaster venules following ischemia-reperfusion injury (76). These anti-inflammatory effects may be linked to TZD-mediated increases in adiponectin. Thus, the chronic inflammation associated with vascular disease in obesity may be mediated in part by the loss of protective, adiponectin-mediated anti-inflammatory effects. It has also been shown that adiponectin plays a role in endogenous antithrombosis (77). Additionally, lowered adiponectin may be related to endothelial dysfunction in obese subjects. A study by Carmina et al. (78) demonstrated that obese women with polycystic ovary syndrome (PCOS) exhibit endothelial dysfunction that correlates with reduced insulin sensitivity and hypoadiponectinemia. Conversely, a recent study by Buras et al. (79) indicates that troglitazone-induced increases in adiponectin concentration are not associated with an improvement in endothelial function in the skin of diabetic humans. One plausible explanation for these disparate findings is differences in the pathophysiologies of PCOS and diabetes.
Most research to date includes characterization of the metabolic effects of adiponectin (much attention given to insulin resistance) and epidemiologic studies demonstrating that hypoadiponectinemia is a risk factor for cardiovascular disease and events of various types (as discussed above). Within the last year a few studies examining the role of adiponectin in coronary vasomotor function have been published. Epicardial adipose tissue produces adiponectin (80). Furthermore, in humans with coronary artery disease, there is a reduction in local epicardial adiponectin production (80). A study by Date et al. (81) using cardiac catheterization techniques measured adiponectin production across the coronary circulation in 22 nondiabetic, healthy subjects with no evidence of coronary artery disease (angiographically normal arteries). Coronary flow reserve was estimated using a Doppler flow wire to measure flow velocities at baseline and maximal hyperemia. Blood samples were simultaneously drawn from the left coronary ostium and the great cardiac vein. The authors observed a significant correlation between coronary flow reserve and the transcardiac adiponectin gradient (i.e., great cardiac vein concentration minus left coronary artery concentration). Those subjects with higher transcardiac adiponectin gradients exhibited higher coronary flow reserves. The study results offer little insight into the precise mechanism of adiponectin-mediated increases in coronary flow reserve, but the data do raise interesting questions that will require further evaluation. Another recent study by Takano et al. (82), using similar techniques as the Date study, found a positive correlation between transcardiac adiponectin gradient and acetylcholine-induced increases in coronary artery diameter—without a correlation between adiponectin gradients and coronary vasomotor responses to nitroprusside or isosorbide dinitrite. The authors concluded that adiponectin plays a role in coronary endothelial function (as assessed by acetylcholine-mediated coronary vasodilation). Of further interest, Takano et al. (82) also studied patient groups with coronary vasospastic angina and microvascular angina. These particular groups exhibited impaired coronary endothelial responses to acetylcholine as expected; however, there was no significant association between coronary endothelial responses and transcardiac adiponectin gradient in the diseased groups. Thus, there is correlative evidence that reduced local cardiac adiponectin production is not only present in individuals with coronary artery disease but may also play a mechanistic role in the associated coronary endothelial dysfunction.
The studies by Date et al. and Takano et al. provide evidence that adiponectin may play a role in coronary vasomotor dysfunction and the pathogenesis of coronary artery disease. To further understand the impact of reduced epicardial adiponectin production in coronary artery disease, studies examining the coronary vasomotor properties of adiponectin on healthy animals, as well as genetically altered animals, might prove helpful. Functional, cellular, and molecular studies in experimental models of obesity would also provide insight into the pathophysiologic mechanisms by which hypoadiponectinemia induces coronary vasomotor dysfunction, which thereby confers heightened risk for coronary artery disease.
|
Resistin |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
In 2003 Verma et al. (88) conducted a study examining the vascular endothelial effects of resistin, so-called adipokine-endothelial cell interactions. Using cultured vascular endothelial cells, Verma et al. demonstrated that resistin activates vascular endothelium, causing release of endothelin-1 (by way of activation of the AP-1 site of the endothelin-1 gene promoter). Additionally, resistin treatment increased endothelial cell expression of vascular cell adhesion molecule 1 and monocyte chemoattractant chemokine 1. Thus, resistin, like leptin, exerts proinflammatory changes in vascular endothelium in experimental settings. As a result, resistin has become an inflammatory marker of atherosclerotic disease (89). However, unlike adiponectin, resistin’s association with markers of inflammation appears to be independent of body mass index (90). Hence, resistin may play a prominent role in the pathogenesis of diabetes-related vascular disease in nonobese subjects. Interestingly, a recent study in the American Journal of Cardiology demonstrated that medical and surgical weight loss improves endothelial function without correlation to plasma resistin levels (91). As with leptin, initial hypotheses surrounding the framework of resistin biology may prove to be false. More studies are needed to define the role of resistin in the pathophysiology of metabolic and inflammatory vascular disease.
As outlined, resistin mediates insulin resistance in many models of obesity. Furthermore, resistin induces marked inflammatory changes in endothelial cell cultures. A recent study indicates that resistin levels are elevated in patients presenting with unstable angina and myocardial infarctions (both non-ST segment elevation myocardial infarction [NSTEMI] and STEMI) and that plasma resistin levels correlate moderately with future cardiovascular death in patients with documented coronary artery disease (92). However, only a few studies to date have examined the direct effects of resistin on the coronary circulation.
A recent study by Kougias et al. (93) demonstrated that treatment of porcine coronary arteries with biologically relevant concentrations (10 ng/ml and 40 ng/ml) of resistin impaired endothelium-dependent relaxation to bradykinin. The impaired relaxation was associated with a marked increase in superoxide anion production. These effects were reversed by the antioxidant seleno-L-methionine. Additionally, treatment of isolated, cultured porcine coronary endothelial cells with resistin resulted in decreased expression of eNOS mRNA levels and eNOS immunoreactivity. Kougias et al. also reported resistin-mediated inhibition (resistin treatment: 40 ng/ml) of coronary vaso-relaxation to sodium nitroprusside and thus concluded that resistin adversely affects endothelium-independent vaso-relaxation as well as coronary endothelial function. The results of the Kougias study implicate resistin as a pro-oxidant mediator of coronary endothelial dysfunction, suggesting a role for resistin in the early pathogenesis of inflammatory coronary endothelial dysfunction in the obese; however, all experiments have been conducted in vitro.
A subsequent study by Dick et al. (94) further examined the effects of resistin on coronary vasomotor function both in vitro and in vivo. Dick et al. studied the hemodynamic effects of intracoronary administration of resistin in open-chest dogs, the effects of resistin on isolated coronary artery vasomotor responses to endothelium-dependent relaxants, and the effects of resistin on coronary artery superoxide anion production in vitro. Intracoronary administration of resistin did not significantly affect coronary blood flow, heart rate, or mean aortic blood pressure in open-chest, anesthetized dogs. In effect, resistin, like leptin, does not directly affect coronary vasomotor tone or systemic hemodynamics when infused into the canine coronary circulation. However, resistin did significantly attenuate coronary blood flow increases to intracoronarily administered bradykinin (Fig. 2B), while not affecting coronary vasodilation to acetylcholine (Fig. 2A). These results were validated in vitro as resistin significantly attenuated canine coronary artery relaxation to bradykinin but not acetylcholine. Thus, resistin, when administered acutely, causes significant coronary endothelial dysfunction in vivo and in vitro. Bradykinin elicits coronary vasodilation in dogs via the production of nitric oxide and other vasoactive substances including prostaglandin I2 and endothelium-derived hyperpolarizing factors (EDHFs) (95). Since resistin-mediated attenuation of bradykinin-induced coronary vasodilation persisted in the presence of L-NAME and indomethacin, Dick et al. concluded that the inhibitory effect of resistin is likely mediated through EDHF(s) or other paracrine mediators. Further studies are needed to address this hypothesis.
|
Taken together, the studies by Kougias et al. and Dick et al. demonstrate that resistin alters coronary vasomotor responses in vivo and in vitro. Although differences in results were present, resistin impaired coronary vasorelaxation to bradykinin in both porcine and canine coronary circulations. With evidence increasing, more studies defining the mechanistic role(s) of resistin in coronary physiology and disease may prove beneficial in advancements in pharmacotherapeutics.
|
Conclusion |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
Much attention has been given to the chronic inflammatory state that accompanies obesity and metabolic syndrome. The focus of this review is the coronary vascular effects of adipokines. Although metabolic syndrome and type 2 diabetes were mentioned several times throughout, a recent review by Matsuzawa (96) discusses adipocytokines in the context of metabolic syndrome in much greater detail. A recent study by Picchi et al. (97) addressed the effects of TNF- on coronary arteriolar endothelial function in animal models of obesity and metabolic syndrome. Picchi et al. concluded that TNF- administration induces endothelial dysfunction (abrogates endothelial-dependent dilation or coronary arterioles isolated from hearts of obese Zucker rats). This result implicates inflammatory cytokines as mediators of coronary dysfunction in obesity; however, with this hypothesis in its infancy, confirmation of the findings by Picchi et al. and others will be necessary for validation.
In recent literature, leptin, adiponectin, and resistin have all been implicated in coronary endothelial dysfunction. The balance of these hormones appears to be crucial for the maintenance of coronary endothelial function. The insulin-resistant state clearly results in the perturbation of leptin, adiponectin, and resistin levels in the blood. Interestingly, studies to date have demonstrated that these three adipokines are each potentially involved in the pathogenesis of coronary artery vasomotor dysfunction, although mechanisms by which these adipokines exert ill effects on the coronary vasculature differ. Leptin and adiponectin appear to be involved in pathways downstream from the acetylcholine receptor. Although not a mediator of physiologic coronary vasodilation, the muscarinic vasodilation pathway is an accepted means of assessing endothelium-dependent vasodilation. Resistin, on the other hand, affects coronary endothelial function from a different angle (the bradykinin pathway).
In conclusion, disruption of physiologic adipokine plasma levels and perturbations in adipokine signaling within the coronary vascular wall culminates in coronary endothelial dysfunction. Thus, alterations in adipokine biology may be a major precipitating factor in the initiation of coronary artery disease in individuals with metabolic disease.
With the incidence of obesity and insulin resistance climbing in Western populations, studies aimed at further characterizing the mechanisms of adipokine-mediated effects on coronary endothelial function are needed if we are to further understand the interplay between the endocrine function of adipose tissue and coronary vasomotor biology. Studies aimed at determining whether there is signaling interplay between adipokines (leptin, adiponectin, and resistin) at vascular targets would also be of interest. Additionally, other molecules receiving attention in obesity research (e.g., ghrelin, orexins, TNF-) should be further studied with respect to the pathogenesis of coronary artery disease.
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionLeptinAdiponectinResistinConclusionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. Broch, M. T. Auguet, R. Ramirez, M. Olona, C. Aguilar, A. Megia, M. J. Alcaide, R. Pastor, S. Martinez, E. Caubet, et al. Parallel downregulation of retinol-binding protein-4 and adiponectin expression in subcutaneous adipose tissue of non-morbidly obese subjects Eur. J. Endocrinol., July 1, 2009; 161(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
